Xenon Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenon Pharmaceuticals Inc. on March 12, 2020. The filing discloses the approval of 2019 non-equity incentive plan payments and 2020 base salaries for the Company's executive officers by the Compensation Committee.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details.
| Executive Officer | Title | 2019 Non-Equity Incentive Payment (USD) | 2020 Base Salary (USD) |
|---|---|---|---|
| Simon N. Pimstone | Chief Executive Officer | $334,266 | $498,149 |
| Ian C. Mortimer | President and CFO | $236,734 | $462,000 |
| Ernesto Aycardi | Chief Medical Officer | $210,000 | $434,700 |
| Robin P. Sherrington | EVP, Strategy & Innovation | $159,604 | $350,410 |
| James R. Empfield | SVP, Drug Discovery | $147,500 | $339,250 |
Note: Payments for Dr. Pimstone, Mr. Mortimer, and Dr. Sherrington were originally in Canadian dollars and converted to USD using an average 2019 exchange rate of 0.7537. 2020 base salaries are retroactive to January 1, 2020.
Material Changes and Outlook
The filing details the establishment of 2020 performance goals tied to corporate objectives. These goals include:
- Top-line data readout for the XEN1101 Phase 2b clinical trial.
- Completion of evaluation to advance XEN1101 in a Phase 2 proof-of-concept non-epilepsy clinical trial.
- Initiation of a Phase 3 clinical trial for XEN496.
- Achievement of Neurocrine partnership milestones regarding regulatory progress and research collaboration.
- Discovery stage goal to transition two projects to lead optimization or lead identification.
- Execution against the Company's capital markets plan and cash-runway objective.
Executive incentive payments for 2020 are based solely on the achievement of these corporate goals, with potential payouts ranging from 40% to 60% of base salary depending on the officer.
Investor Verification Checklist
- Verify the status of the XEN1101 Phase 2b and XEN496 Phase 3 clinical trials to assess the likelihood of meeting executive performance goals.
- Review the Company's cash runway and capital markets plan to ensure sufficient liquidity to fund operations and meet the salary obligations outlined.
- Confirm the exchange rate impact on executive compensation for officers paid in Canadian dollars versus the USD benchmarked salaries.
- Check for any subsequent filings regarding the Neurocrine partnership milestones mentioned in the performance goals.